CAMBRIDGE, Mass. – Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today the enrollment of the first subject in a natural history study dedicated to patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). ALSP is a rare, genetically...
Latest News
WATERTOWN, Mass. — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced multiple oral and poster presentations on adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) at the 2023 American Academy of Neurology (AAN)...
SAN DIEGO — Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per...
PALO ALTO, Calif. — Vincerx Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for the treatment of relapsed/refractory lymphoma. “Enitociclib...
SAN FRANCISCO, Calif. – VIR BIOTECHNOLOGY Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier...
BUFFALO, NY – A new research paper was published in Oncotarget’s Volume 15 on March 5, 2024, entitled, “GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.” In this new study, researchers Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent from Virginia Commonwealth University and Genzada Pharmaceuticals...
Blacksburg, Virginia – A team of Virginia Tech researchers was awarded nearly $2 million from the National Institute of Diabetes and Digestive and Kidney Disease, part of the National Institutes of Health, to explore novel approaches for treating Type 2 diabetes and obesity. Type 2 diabetes affects more than 38.4...
Blacksburg, Virginia – Living organisms often create what is needed for life from scratch. For humans, this process means the creation of most essential compounds needed to survive. But not every living thing has this capability, such as the parasite that causes malaria, which affected an estimated 249 million people...
Blacksburg, VA – Cancer is the monster of our society. Last year alone, more than 600,000 people in the United States died from cancer, according to the American Cancer Society. The relentless pursuit of understanding this complex disease has shaped medical progress on developing treatment procedures that are less invasive...
Blacksburg, VA – For many patients with a deadly type of brain cancer called glioblastoma, chemotherapy resistance is a big problem. Current standard treatments, including surgery, radiation, and chemotherapy using the drug temozolomide, have limited effectiveness and have not significantly changed in the past five decades. Although temozolomide can initially slow...